[go: up one dir, main page]

AUPR593101A0 - Cytomegalovirus t cell epitopes - Google Patents

Cytomegalovirus t cell epitopes

Info

Publication number
AUPR593101A0
AUPR593101A0 AUPR5931A AUPR593101A AUPR593101A0 AU PR593101 A0 AUPR593101 A0 AU PR593101A0 AU PR5931 A AUPR5931 A AU PR5931A AU PR593101 A AUPR593101 A AU PR593101A AU PR593101 A0 AUPR593101 A0 AU PR593101A0
Authority
AU
Australia
Prior art keywords
cytomegalovirus
cell epitopes
epitopes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR5931A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Priority to AUPR5931A priority Critical patent/AUPR593101A0/en
Publication of AUPR593101A0 publication Critical patent/AUPR593101A0/en
Priority to EP02737666.4A priority patent/EP1409527B1/en
Priority to DK02737666.4T priority patent/DK1409527T3/en
Priority to ES02737666.4T priority patent/ES2523972T3/en
Priority to US10/482,284 priority patent/US7524503B2/en
Priority to AU2002312654A priority patent/AU2002312654B2/en
Priority to PCT/AU2002/000829 priority patent/WO2003000720A1/en
Priority to JP2003507123A priority patent/JP4574166B2/en
Priority to CA002451328A priority patent/CA2451328A1/en
Priority to US12/382,425 priority patent/US20100183647A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AUPR5931A 2001-06-26 2001-06-26 Cytomegalovirus t cell epitopes Abandoned AUPR593101A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AUPR5931A AUPR593101A0 (en) 2001-06-26 2001-06-26 Cytomegalovirus t cell epitopes
CA002451328A CA2451328A1 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
US10/482,284 US7524503B2 (en) 2001-06-26 2002-06-26 Human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
DK02737666.4T DK1409527T3 (en) 2001-06-26 2002-06-26 NOVEL cytotoxic T cell epitopes AND polyepitopes human cytomegalovirus (HCMV), compositions comprising them and diagnostic and prophylactic and therapeutic uses thereof
ES02737666.4T ES2523972T3 (en) 2001-06-26 2002-06-26 New epitopes of cytotoxic T lymphocytes of human cytomegalovirus (HCMV), polyepitopes, compositions comprising them, and diagnostic and prophylactic and therapeutic uses for them
EP02737666.4A EP1409527B1 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
AU2002312654A AU2002312654B2 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
PCT/AU2002/000829 WO2003000720A1 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
JP2003507123A JP4574166B2 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions containing them, and their diagnostic, prophylactic and therapeutic uses
US12/382,425 US20100183647A1 (en) 2001-06-26 2009-03-16 Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR5931A AUPR593101A0 (en) 2001-06-26 2001-06-26 Cytomegalovirus t cell epitopes

Publications (1)

Publication Number Publication Date
AUPR593101A0 true AUPR593101A0 (en) 2001-07-19

Family

ID=3829899

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPR5931A Abandoned AUPR593101A0 (en) 2001-06-26 2001-06-26 Cytomegalovirus t cell epitopes
AU2002312654A Expired AU2002312654B2 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002312654A Expired AU2002312654B2 (en) 2001-06-26 2002-06-26 Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor

Country Status (8)

Country Link
US (2) US7524503B2 (en)
EP (1) EP1409527B1 (en)
JP (1) JP4574166B2 (en)
AU (2) AUPR593101A0 (en)
CA (1) CA2451328A1 (en)
DK (1) DK1409527T3 (en)
ES (1) ES2523972T3 (en)
WO (1) WO2003000720A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101534A1 (en) * 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
US20050232933A1 (en) * 2003-09-30 2005-10-20 Zaia John A CMV-IE1 peptides and method of use
AU2012227280B2 (en) * 2004-11-29 2016-09-22 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
US20080138354A1 (en) * 2006-07-21 2008-06-12 City Of Hope Cytomegalovirus vaccine
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
EP2303319B1 (en) 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2420572B1 (en) * 2009-04-01 2015-03-25 Evec Incorporated Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof
EP2471553A4 (en) * 2009-06-26 2013-08-28 Vectorite Biomedica Inc An immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof
AT508569A1 (en) 2009-07-23 2011-02-15 Affiris Ag PHARMACEUTICAL COMPOUND
WO2011024482A1 (en) * 2009-08-29 2011-03-03 株式会社バイオメッドコア Method for measurement of ability of inducing antigen-specific t cells
AU2010313339B2 (en) * 2009-10-30 2016-05-26 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP5712513B2 (en) * 2010-07-07 2015-05-07 富士レビオ株式会社 Method for detecting human cytomegalovirus infection
CN101948051A (en) * 2010-08-31 2011-01-19 佛山市南海瑞洲科技有限公司 Conveying worktable with adsorption function
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
RU2670745C9 (en) * 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Individualised vaccines for cancer
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
AU2013332272B2 (en) * 2012-10-19 2018-12-20 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
HK1226299A1 (en) * 2013-09-24 2017-09-29 Duke University Compositions, methods and kits for eliciting an immune response
CA2971288A1 (en) * 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
WO2017079747A1 (en) 2015-11-06 2017-05-11 Regents Of The University Of Minnesota Activation of resident memory t cells for cancer immunotherapy
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
US20200316119A1 (en) * 2016-05-23 2020-10-08 The Counsil of the Queensland Institute of Medical REsearch Cmv epitopes
KR102879364B1 (en) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer
CA3071583A1 (en) * 2017-08-03 2019-02-07 Regents Of The University Of Minnesota Activation of resident memory t cells for the treatment of cancer
KR20250044945A (en) 2017-11-06 2025-04-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Cancer treatment utilizing pre-existing microbial immunity
EP3814367A4 (en) * 2018-05-18 2022-05-04 The Council Of The Queensland Institute Of Medical Research ADOPTIVE T-CELL THERAPY FOR CMV INFECTION AND CMV-ASSOCIATED DISEASES
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11471526B2 (en) 2019-02-22 2022-10-18 University Of Maryland, College Park FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease
WO2021038062A1 (en) * 2019-08-29 2021-03-04 Eberhard Karls Universität Tübingen, Medizinische Fakultät T cell epitopes of hcmv and uses of thereof
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
US20240002902A1 (en) 2022-05-06 2024-01-04 10X Genomics, Inc. Analysis of antigen and antigen receptor interactions
CN115894708B (en) * 2022-08-16 2023-10-10 青岛大学 Human cytomegalovirus epitope chimeric peptide and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242567B1 (en) * 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
WO1994023744A1 (en) * 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
IT1266740B1 (en) * 1994-07-01 1997-01-14 Maria Paola Landini RECOMBINANT PROTEIN MATERIAL BINDING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS, DIAGNOSTIC REAGENTS DERIVED FROM THIS
WO1998002746A1 (en) 1996-07-12 1998-01-22 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (cmv)
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6074645A (en) * 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
ATE262539T1 (en) 1996-11-12 2004-04-15 Hope City IMMUNOREACTIVE PEPTIDE CTL EPITOPES OF HUMAN CYTOMEGALOVIRUS
DE19919121B4 (en) * 1999-04-27 2012-08-02 F. Hoffmann-La Roche Ag Multimeric CMV antigen
WO2000075180A2 (en) * 1999-06-04 2000-12-14 Florian Kern Peptides for vaccinating against human cmv

Also Published As

Publication number Publication date
EP1409527A4 (en) 2005-08-17
EP1409527A1 (en) 2004-04-21
US20050019344A1 (en) 2005-01-27
DK1409527T3 (en) 2014-11-24
WO2003000720A1 (en) 2003-01-03
AU2002312654B2 (en) 2009-01-08
JP2005504733A (en) 2005-02-17
ES2523972T3 (en) 2014-12-03
EP1409527B1 (en) 2014-08-20
JP4574166B2 (en) 2010-11-04
CA2451328A1 (en) 2003-01-03
US20100183647A1 (en) 2010-07-22
US7524503B2 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
AUPR593101A0 (en) Cytomegalovirus t cell epitopes
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002368042A1 (en) Photovoltaic cell
AU2002309771A1 (en) Monoblock battery
AU2002366160A1 (en) Zinc-alkaline battery containing lambda-mn02
AU2003241860A1 (en) Sealed nickel-zinc primary cell
AU2002360007A1 (en) Fuel cell
AUPR831501A0 (en) Fusion reactor
AU2002354275A1 (en) Fuel cell-use separator
AU2002304886A1 (en) Fuel cell
AU2002349713A1 (en) Nickel-hydrogen cell
AU2002359464A1 (en) Angiopioetin related factors
AUPR584801A0 (en) Memory jogger
AU2002242602A1 (en) Reactor
AU2002361852A1 (en) Potassium fluoroionophore
AU2002254161A1 (en) M cell directed vaccines
AUPR706301A0 (en) An impact-absorbing cell
AU2002338718A1 (en) High-temperature accumulator
AUPR964501A0 (en) Backpack
AU2002248451A1 (en) Cerium batteries
AU2002222318A1 (en) Cell phone - hand set combination unit
AU2002253052A1 (en) Separator
AU2002362345A1 (en) Hybrid cell
AU2002322164A1 (en) An impact-absorbing cell
AU2001240897A1 (en) Epitopes